Voyager Therapeutics (VYGR) & Ionis Pharmaceuticals (IONS) Financial Comparison
Voyager Therapeutics (NASDAQ: VYGR) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.
Valuation & Earnings
This table compares Voyager Therapeutics and Ionis Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Voyager Therapeutics||$8.31 million||55.52||-$59.32 million||($2.30)||-7.46|
|Ionis Pharmaceuticals||$485.73 million||15.12||$80.88 million||$0.21||281.30|
Ionis Pharmaceuticals has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Voyager Therapeutics has a beta of 3.65, indicating that its stock price is 265% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 3.13, indicating that its stock price is 213% more volatile than the S&P 500.
This table compares Voyager Therapeutics and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for Voyager Therapeutics and Ionis Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Voyager Therapeutics presently has a consensus price target of $24.83, indicating a potential upside of 44.80%. Ionis Pharmaceuticals has a consensus price target of $49.46, indicating a potential downside of 16.27%. Given Voyager Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Voyager Therapeutics is more favorable than Ionis Pharmaceuticals.
Institutional and Insider Ownership
40.7% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 89.2% of Ionis Pharmaceuticals shares are owned by institutional investors. 6.0% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Ionis Pharmaceuticals beats Voyager Therapeutics on 7 of the 13 factors compared between the two stocks.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain. The Company’s clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson’s disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.